Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hematopoietic Stem Cell Transplantation"" wg kryterium: Temat


Tytuł :
Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
Autorzy :
Wei H; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Kuang P; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Liu T; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2619-2628. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Philadelphia Chromosome*
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adult ; Allografts ; Autografts ; Disease-Free Survival ; Female ; Humans ; Male ; Survival Rate
Czasopismo naukowe
Tytuł :
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
Autorzy :
Zhao JY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Liu SN; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.
Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chen YH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China.; Peking-Tsinghua Center for Life Sciences, Beijing, 100044, China.
Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. .; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 169-180. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Cyclophosphamide*
Hematopoietic Stem Cell Transplantation*/trends
Salvage Therapy*/trends
Transplantation, Haploidentical*/trends
Drug Resistance, Multiple/*drug effects
Graft vs Host Disease/*drug therapy
Pyrazoles/*therapeutic use
Adolescent ; Adult ; Child ; Child, Preschool ; Drug Resistance, Multiple/physiology ; Female ; Follow-Up Studies ; Graft vs Host Disease/diagnosis ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Transplantation, Homologous/trends ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.
Autorzy :
Del Galy AS; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.; University of Paris, Paris, France.
Marouf A; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.
Raffoux E; Adult Hematology, AP-HP Hospital St Louis, Paris, France.
Robin M; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.
Michonneau D; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.; University of Paris, Paris, France.; INSERM UMR 976, Paris, France.
Sébert M; Hematology Senior, AP-HP Hospital St Louis, Paris, France.
Sicre de Fontebrune F; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.
Xhaard A; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.
Lengline E; Adult Hematology, AP-HP Hospital St Louis, Paris, France.
Itzykson R; University of Paris, Paris, France.; Adult Hematology, AP-HP Hospital St Louis, Paris, France.
Frieri C; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.; University of Paris, Paris, France.
Dombret H; University of Paris, Paris, France.; Adult Hematology, AP-HP Hospital St Louis, Paris, France.
Fenaux P; University of Paris, Paris, France.; Hematology Senior, AP-HP Hospital St Louis, Paris, France.
Peffault de Latour R; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.; University of Paris, Paris, France.
Adès L; University of Paris, Paris, France.; Hematology Senior, AP-HP Hospital St Louis, Paris, France.
Socié G; Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France. .; University of Paris, Paris, France. .; INSERM UMR 976, Paris, France. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 225-228. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Letter
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute/*therapy
Myelodysplastic Syndromes/*therapy
Age Factors ; Aged ; Aged, 80 and over ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/mortality ; Transplantation, Homologous ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
Autorzy :
Hernández-Boluda JC; Hematology Department, Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain. .
Pereira A; Hemotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain.
Kröger N; University Hospital Eppendorf, Hamburg, Germany.
Beelen D; University Hospital, Essen, Germany.
Robin M; Hopital Saint Louis, Assistance Publique Hôpitaux de Paris, Université Paris 7, Paris, France.
Bornhäuser M; University Hospital, TU Dresden, Dresden, Germany.
Angelucci E; Ospedale San Martino, Genoa, Italy.
Vitek A; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Blau IW; Charité Universitaetsmedizin, Berlin, Germany.
Niittyvuopio R; HUCH Comprehensive Cancer Center, Helsinki, Finland.
Finke J; Division of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center University of Freiburg, Freiburg, Germany.
Cornelissen JJ; Erasmus MC Cancer Center, Rotterdam, The Netherlands.
Passweg J; University Hospital, Basel, Switzerland.
Dreger P; University of Heidelberg, Heidelberg, Germany.
Petersen E; University Medical Center, Utrecht, The Netherlands.
Kanz L; Universitaet Tuebingen, Tuebingen, Germany.
Sanz J; University Hospital La Fe, Valencia, Spain.
Zuckerman T; Rambam Medical Center, Haifa, Israel.
Zinger N; EBMT Data Office Leiden, Leiden, The Netherlands.
Iacobelli S; Department of Biology, University of Rome Tor Vergata, Rome, Italy.
Hayden P; Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.
Czerw T; Maria Skłodowska-Curie Institute-Cancer Center, Gliwice, Poland.
McLornan D; Departments of Haematology and Stem Cell Transplantation, Guys' and St. Thomas' NHS Foundation Trust and University College London Hospitals, London, UK.
Yakoub-Agha I; CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 215-224. Date of Electronic Publication: 2020 Apr 14.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Primary Myelofibrosis/*mortality
Primary Myelofibrosis/*therapy
Europe ; Female ; Graft vs Host Disease/etiology ; Humans ; Kaplan-Meier Estimate ; Male ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/epidemiology ; Prognosis ; Proportional Hazards Models ; Recurrence ; Registries ; Retrospective Studies ; Transplantation, Homologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome.
Autorzy :
Zhou M; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Wu L; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Zhang Y; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Mo W; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Li Y; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Chen X; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Wang C; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Pan S; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Xu S; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Zhou W; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Deng T; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China.
Wang S; Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, 1 Panfu Road, Guangzhou, 510180, Guangdong, People's Republic of China. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 825-834. Date of Electronic Publication: 2020 Aug 16.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Myelodysplastic Syndromes/*therapy
Adolescent ; Adult ; Disease-Free Survival ; Female ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/etiology ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes/blood ; Myelodysplastic Syndromes/mortality ; Retrospective Studies ; Survival Rate ; Time Factors ; Tissue Donors ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Autorzy :
Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China. .
Zhao YL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Zhang JP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Xiong M; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Cao XY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Liu DY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Wei ZJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Zhou JR; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China Si Pu Lan Road, Yanjiao Development Zone, Langfang, 065201, Hebei, China.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2911-2925. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Living Donors*
Siblings*
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*therapy
Transplantation, Haploidentical/*methods
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/trends ; Histocompatibility Testing/methods ; Histocompatibility Testing/trends ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Transplantation Conditioning/methods ; Transplantation Conditioning/trends ; Transplantation, Haploidentical/trends ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma.
Autorzy :
Carella M; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Stefoni V; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Pellegrini C; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Argnani L; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Cavo M; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Zinzani PL; Institute of Haematology 'L. e A. Seràgnoli,' University of Bologna, Bologna, Italy.
Pokaż więcej
Źródło :
Tumori [Tumori] 2020 Dec; Vol. 106 (6), pp. NP5-NP8. Date of Electronic Publication: 2020 May 22.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Lymphoma, Follicular/*pathology
Lymphoma, Follicular/*therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Female ; Humans ; Magnetic Resonance Imaging ; Middle Aged ; Neoplasm Staging ; Recurrence ; Retreatment ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19.
Autorzy :
Lázaro Del Campo P; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
de Paz Arias R; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
Ramírez López A; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
de la Cruz Benito B; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
Humala Barbier K; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
Sánchez Vadillo I; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
López de la Guía A; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
de Soto Álvarez T; La Paz University Hospital, Hematology Department, Madrid, Spain. Electronic address: .
Jiménez Yuste V; La Paz University Hospital, Hematology Department, Madrid, Spain; Autonoma University of Madrid, Spain. Electronic address: .
Canales Albendea M; La Paz University Hospital, Hematology Department, Madrid, Spain; Autonoma University of Madrid, Spain. Electronic address: .
Pokaż więcej
Źródło :
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2020 Dec; Vol. 59 (6), pp. 102921. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji :
Letter
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lymphoma, Mantle-Cell*/blood
Lymphoma, Mantle-Cell*/therapy
SARS-CoV-2*
Tissue Donors*
COVID-19/*blood
Allografts ; Female ; Humans ; Male ; Middle Aged
Opinia redakcyjna
Tytuł :
Effects of partly supervised and home-based exercise program in patients undergoing hematopoietic stem cell transplantation: a case-control study.
Autorzy :
Yildiz Kabak V; Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Turkey. .
Goker H; Faculty of Medicine, Department of Hematology, Hacettepe University, Ankara, Turkey.
Duger T; Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Turkey.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Dec; Vol. 28 (12), pp. 5851-5860. Date of Electronic Publication: 2020 Apr 06.
Typ publikacji :
Journal Article
MeSH Terms :
Cognition/*physiology
Exercise Therapy/*methods
Fatigue/*psychology
Hematopoietic Stem Cell Transplantation/*psychology
Muscle Strength/*physiology
Quality of Life/*psychology
Adult ; Case-Control Studies ; Exercise/physiology ; Female ; Hand Strength/physiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Autorzy :
Borlenghi E; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Cattaneo C; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Cerqui E; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Archetti S; Diagnostic Department, Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.
Bertoli D; Diagnostic Department, Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.
Bellotti D; Laboratorio di Citogenetica e Genetica Medica, ASST Spedali Civili, Brescia, Italy.
Gramegna D; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Soverini G; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Oberti M; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Schieppati F; Immunohematology and Trasfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Pagani C; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Passi A; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Sciumé M; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Farina M; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Carbone C; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Crippa C; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Dalceggio D; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Tucci A; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Rossi G; Hematology Department, ASST Spedali Civili, Brescia, Italy.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 754-762. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Combined Modality Therapy ; Cytarabine/adverse effects ; Cytarabine/therapeutic use ; Daunorubicin/adverse effects ; Daunorubicin/therapeutic use ; Female ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/etiology ; Male ; Middle Aged ; Prognosis ; Survival Analysis ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
SCR Protocol :
HDAC protocol
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient.
Autorzy :
Fujiwara Y; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Matsuoka KI; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan. .
Iwamoto M; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Sumii Y; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Abe M; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Mizuhara K; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Urata T; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Saeki K; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Meguri Y; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Asada N; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Ennishi D; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Nishimori H; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Fujii K; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Fujii N; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Sugita J; Department of Hematology, Hokkaido University Hospital, Hokkaido, Japan.
Kobayashi H; Department of Hematology, Obihiro Kosei Hospital, Hokkaido, Japan.
Oto T; Department of Organ Transplant Center, Okayama University Hospital, Okayama, Japan.
Maeda Y; Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Dec; Vol. 112 (6), pp. 871-877. Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Lung Transplantation*
Bronchiolitis Obliterans/*surgery
Myelodysplastic Syndromes/*therapy
Adult ; Bronchiolitis Obliterans/complications ; Feasibility Studies ; Humans ; Immune Tolerance ; Lung/immunology ; Male ; Myelodysplastic Syndromes/etiology ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.
Autorzy :
Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. .; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. .
Mikulska M; Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.
de la Camara R; Department of Hematology, Hospital de la Princesa, Madrid, Spain.
Basak GW; Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Chabannon C; Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.
Corbacioglu S; Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.
Duarte R; Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Dolstra H; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Lankester AC; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, the Netherlands.
Mohty M; Department of Hematology, Hospital Saint Antoine, Paris, France.
Montoto S; St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Murray J; The Christie NHS Foundation Trust, Manchester, UK.
Peffault de Latour R; BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Yakoub-Agha I; CHU de Lille, Univ Lille, INSERM, U1285, Lille, France.
Verhoeven B; Foundation Hematon, Utrecht, the Netherlands.
Kröger N; Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Styczynski J; Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
Pokaż więcej
Corporate Authors :
European Society for Blood and Marrow Transplantation
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2020 Nov; Vol. 55 (11), pp. 2071-2076. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Practice Guideline; Review
MeSH Terms :
Betacoronavirus*
Coronavirus Infections*/diagnosis
Coronavirus Infections*/epidemiology
Coronavirus Infections*/prevention & control
Hematopoietic Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/statistics & numerical data
Immunotherapy, Adoptive*
Pandemics*/prevention & control
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/prevention & control
Delivery of Health Care/*standards
Infection Control/*standards
Accreditation/organization & administration ; Allografts ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Continuity of Patient Care ; Cross Infection/prevention & control ; Europe ; Health Personnel ; Humans ; Immunocompromised Host ; Infectious Disease Transmission, Patient-to-Professional/prevention & control ; Infectious Disease Transmission, Professional-to-Patient/prevention & control ; Office Visits ; Procedures and Techniques Utilization ; SARS-CoV-2 ; Telemedicine ; Tissue Donors ; Transplant Recipients ; Transplantation, Autologous ; Visitors to Patients
Czasopismo naukowe
Tytuł :
Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation.
Autorzy :
Meng XY; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Fu HX; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Zhu XL; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Wang JZ; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Liu X; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Yan CH; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Zhang YY; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Mo XD; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Wang Y; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Han W; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Chen YH; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Chen DB; Department of Pathology, Peking University People's Hospital, Beijing, China.
Liu HX; Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing, China.
Chang YJ; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Xu LP; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Liu KY; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Huang XJ; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China.; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; National Clinical Research Center for Hematologic Disease, Beijing, China.
Zhang XH; Peking University Institute of Hematology, Peking University People's Hospital, Xicheng District Xizhimen South Street No. 11, Beijing, 100044, China. .; Collaborative Innovation Center of Hematology, Peking University, Beijing, China. .; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. .; National Clinical Research Center for Hematologic Disease, Beijing, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2659-2670. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article
MeSH Terms :
Cytomegalovirus*
Cytomegalovirus Infections*/diagnosis
Cytomegalovirus Infections*/etiology
Cytomegalovirus Infections*/mortality
Cytomegalovirus Infections*/therapy
Hematopoietic Stem Cell Transplantation*
Adolescent ; Adult ; Allografts ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Survival Rate ; Time Factors
Czasopismo naukowe
Tytuł :
Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia.
Autorzy :
Yu J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Ge X; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Luo Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Shi J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Tan Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Lai X; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Zhao Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Ye Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Zhu Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Zheng W; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China. .; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2639-2648. Date of Electronic Publication: 2020 Sep 05.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adult ; Allografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Risk Factors ; Survival Rate
Czasopismo naukowe
Tytuł :
Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
Autorzy :
Murt A; Cerrahpasa Medical Faculty, Internal Medicine Department, Nephrology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey. .
Elverdi T; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Eskazan AE; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Salihoglu A; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Ar MC; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Ongoren S; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Baslar Z; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Soysal T; Cerrahpasa Medical Faculty, Internal Medicine Department, Hematology Section, Istanbul University - Cerrahpasa, Istanbul, Turkey.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2671-2677. Date of Electronic Publication: 2020 Jul 31.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Virus Activation*
Hepatitis B Antibodies/*blood
Hepatitis B Surface Antigens/*blood
Hepatitis B virus/*physiology
Hepatitis B, Chronic/*blood
Immunoglobulin G/*blood
Adult ; Allografts ; Autografts ; Female ; Hepatitis B, Chronic/prevention & control ; Humans ; Incidence ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Autorzy :
Yu J; US Medical Affairs, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA. .
Lal L; Optum, Inc., 11000 Optum Circle, Eden Prairie, MN, 55344, USA.
Anderson A; Optum, Inc., 11000 Optum Circle, Eden Prairie, MN, 55344, USA.
DuCharme M; Optum, Inc., 11000 Optum Circle, Eden Prairie, MN, 55344, USA.
Parasuraman S; US Medical Affairs, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
Weisdorf D; University of Minnesota, 516 Delaware St SE, Minneapolis, MN, 55455, USA.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5491-5499. Date of Electronic Publication: 2020 Mar 14.
Typ publikacji :
Journal Article
MeSH Terms :
Graft vs Host Disease/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Adolescent ; Adult ; Aged ; Child ; Female ; Graft vs Host Disease/economics ; Graft vs Host Disease/etiology ; Health Resources/statistics & numerical data ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/economics ; Hematopoietic Stem Cell Transplantation/statistics & numerical data ; Humans ; Male ; Middle Aged ; Patient Acceptance of Health Care/statistics & numerical data ; Retrospective Studies ; Transplantation, Homologous ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Autorzy :
Luo XY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Mo XD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Chang YJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
Zhao XY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China. .
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2649-2657. Date of Electronic Publication: 2020 Mar 24.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Epstein-Barr Virus Infections*/drug therapy
Epstein-Barr Virus Infections*/etiology
Epstein-Barr Virus Infections*/mortality
Hematopoietic Stem Cell Transplantation*
Herpesvirus 4, Human*
Lymphoproliferative Disorders*/drug therapy
Lymphoproliferative Disorders*/etiology
Lymphoproliferative Disorders*/mortality
Rituximab/*administration & dosage
Adolescent ; Adult ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Incidence ; Lymphocyte Depletion ; Male ; Middle Aged ; Retrospective Studies ; Rituximab/adverse effects ; Survival Rate
Czasopismo naukowe
Tytuł :
Oral chronic graft-versus-host disease: What the general dental practitioner needs to know.
Autorzy :
Haverman TM
Raber-Durlacher JE
Raghoebar II
Rademacher WMH
Rozema FR
Hazenberg MD
Epstein JB
Treister NS
Pokaż więcej
Źródło :
Journal of the American Dental Association (1939) [J Am Dent Assoc] 2020 Nov; Vol. 151 (11), pp. 846-856.
Typ publikacji :
Journal Article
MeSH Terms :
Graft vs Host Disease*/diagnosis
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Chronic Disease ; Dentists ; Humans ; Professional Role
Czasopismo naukowe
Tytuł :
COVID-19 pandemic and impact on hematopoietic stem cell transplantation.
Autorzy :
Sahu KK; Division of Hematology and Oncology, Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States. .
Siddiqui AD; Division of Hematology and Oncology, Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States.
Cerny J; Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, Worcester, Massachusetts, United States.
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2020 Nov; Vol. 55 (11), pp. 2193-2195. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Letter
MeSH Terms :
Betacoronavirus*
Coronavirus Infections*/diagnosis
Coronavirus Infections*/epidemiology
Coronavirus Infections*/prevention & control
Hematopoietic Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/statistics & numerical data
Pandemics*/prevention & control
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/prevention & control
Practice Guidelines as Topic*
Infection Control/*standards
COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Cross Infection/prevention & control ; Donor Selection ; Europe ; Humans ; Infectious Disease Transmission, Patient-to-Professional/prevention & control ; Infectious Disease Transmission, Professional-to-Patient/prevention & control ; Patient Care Team ; Procedures and Techniques Utilization ; SARS-CoV-2 ; Tissue Donors ; Transplant Recipients
Opinia redakcyjna
Tytuł :
Overcoming barriers for the establishment of a consolidated hematopoietic cell transplantation program in a developing country.
Autorzy :
Rivera-Franco MM; Hematopoietic Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Belisario Dominguez Seccion XVI, Tlalpan, 14080, Mexico City, Mexico.
Leon-Rodriguez E; Hematopoietic Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Belisario Dominguez Seccion XVI, Tlalpan, 14080, Mexico City, Mexico. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 Nov; Vol. 112 (5), pp. 707-713. Date of Electronic Publication: 2020 Aug 01.
Typ publikacji :
Journal Article
MeSH Terms :
Developing Countries*
Hematopoietic Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/mortality
Program Development*
Adolescent ; Adult ; Aged ; Bone Marrow Transplantation ; Female ; Humans ; Male ; Mexico ; Middle Aged ; Retrospective Studies ; Survival Rate ; Tertiary Care Centers ; Transplantation, Autologous ; Transplantation, Homologous ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies